Compass Therapeutics (CMPX) Change in Cash (2018 - 2026)

Compass Therapeutics has reported Change in Cash for 9 years, with the latest figure at $24.5 million in Q1 2026.

• Quarterly Change in Cash rose 1107.19% year-over-year to $24.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.1 million (down 18.73% YoY) and the FY2025 annual result came in at -$12.8 million, down 166.68% from the prior year.
• Change in Cash advanced to $24.5 million in Q1 2026 per CMPX's latest filing, from -$15.6 million in the prior quarter.
• Over five years, Change in Cash peaked at $24.5 million in Q1 2026 and troughed at -$110.1 million in Q2 2022.
• A 5-year average of -$5.3 million and a median of -$4.3 million in 2024 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2026: Change in Cash plunged 1206.85% in 2022, then surged 1107.19% in 2026.
• Over 5 years, Change in Cash stood at $18.5 million in 2022, then tumbled by 133.57% to -$6.2 million in 2023, then surged by 198.64% to $6.1 million in 2024, then plunged by 354.65% to -$15.6 million in 2025, then surged by 257.52% to $24.5 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $24.5 million, -$15.6 million, and $23.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.